16.01.2014 • News

Evonik Venture Capital Invests in FRX Polymers

With a $2.5 million cash injection, the venture capital fund of Germany's Evonik has led a $12 million series C financing round in U.S.-based FRX Polymers. Under the Nofia trademark, the company headquartered at Chelmsford, Massachusetts, manufactures and markets what it says is an environmentally friendly family of non-halogenated flame retardant plastics and oligomers based on polyphosphonate.

Evonik's funds injection coincided with the opening of FRX's first industrial-scale flame retardant polymer plant at Antwerp, Belgium. The U.S. company already operates two pilot plants at Chelmsford and another in Switzerland. Other investors in the series C round include Capricorn Venture Partners, DB Masdar, SAM Private Equity, BASF Venture Capital, Israel Cleantech Ventures, and a western Canadian syndicate. In its last round of fundraising,Series B, in March 2012, FRX took in $26.7 million.

The FRX polymers, designed to replace brominated FR systems, are used in a wide variety of electronics, building & construction, fiber, and transportation applications. The Nofia polyphosphonates have little impact on the inherent mechanical properties of the host resin, according to the company's CEO, Marc Lebel.

Interview

Leading Transformation
The Path to Sustainable Growth

Leading Transformation

As Executive Vice President of International Chemicals since early 2024, Antje Gerber has been steering Sasol through a pivotal reset—focused on resilience, innovation, and bold sustainability goals.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read